Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA reports news on its AI-driven precision medicine software business and the adoption of the SOPHiA DDM Platform by hospitals, laboratories, and biopharma institutions. Company updates commonly cover financial results, analysis volumes, customer additions, U.S. market expansion, and applications that analyze genomic and multimodal data for cancer and rare disorders.
Recurring developments include health-system collaborations, next-generation sequencing workflows for blood cancers and solid tumors, Liquid Biopsy and Enhanced Exomes applications, and management commentary on platform demand, gross margin, operating leverage, and biopharma activity.
SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2021 financial results on September 9, 2021, before market open. The management will host a conference call at 8:30 a.m. ET to discuss these results, alongside business developments and future outlook. The company focuses on data-driven medicine and operates the SOPHiA DDM™ Platform, utilized by over 780 institutions globally. A live webcast of the call will be accessible in the 'Investors' section of their website, with an archived replay available post-event.
SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q2 2021 on September 9, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss these results, business developments, and future outlook. The company emphasizes its commitment to data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 780 healthcare institutions globally, reinforcing its strategic position in the healthcare technology landscape.
Dasa, Brazil's largest healthcare network, is expanding its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to launch the first decentralized HRD analytics solution in Latin America. This solution focuses on identifying cancer patients who may benefit from PARP inhibitors, promoting personalized therapies. With over 20 million patient interactions yearly, Dasa enhances its genomic capabilities using SOPHiA's platform, built on a collaboration that started in 2016. This innovation aims to improve patient outcomes through efficient data management and tailored treatment strategies.
SOPHiA GENETICS (Nasdaq: SOPH) has successfully closed its initial public offering, selling 13,000,000 ordinary shares at $18 each, generating gross proceeds of $234 million. Following this, the company also completed a private placement, issuing 1,111,111 ordinary shares to GE Healthcare for $20 million. The new shares began trading on the Nasdaq on July 23, 2021. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse were joint book-running managers for the IPO.
SOPHiA GENETICS has announced the pricing of its initial public offering (IPO) of 13,000,000 ordinary shares at $18 each, aiming to raise around $234 million in gross proceeds. The IPO is set to trade on the Nasdaq under the symbol 'SOPH' starting July 23, 2021, with the closing expected on July 27, 2021. Additionally, underwriters have a 30-day option to purchase up to 1,950,000 more shares. The company specializes in data-driven medicine through its SOPHiA DDM™ Platform, which serves over 780 institutions worldwide.